RE: Edison Research Note17 Aug 2019 10:00
Given forecast revenues are in excess of $1000m by 2028 and a p/s of 18, a p/e of 50 and net margins of circa 20% I calculate we will be at around £17 by 2028 which is my timescale. £6 - £7 in 2 to 3 years is realistic if the pipeline continues, and we get NDA's for Surufatinib, and crucially for Savolotinib in the United States, which starts to feed through to revenues and royalties.